Citeline, Risklick Partner to Improve Protocol Design and Optimization

Why It Matters

The partnership tackles rising amendment costs and delays, giving sponsors a faster, data‑driven path to trial initiation and potentially improving enrollment success.

Key Takeaways

• Protocol amendments cost $140k‑$500k each.
• AI reduces amendment risk and speeds timelines.
• Integrated workflow spans design to regulatory disclosure.
• Citeline provides data‑driven endpoint optimization.
• Risklick aims for one‑day trial design.

Pulse Analysis

The clinical trial landscape has been plagued by an escalating frequency of protocol amendments, a trend that began in 2015 and now represents a major financial drain for sponsors. Each amendment can add between $140,000 and $500,000 to a study’s budget, while also extending timelines and jeopardizing patient enrollment. As regulatory agencies demand greater transparency and patient‑centric designs, pharmaceutical companies are under pressure to deliver near‑perfect protocols on the first attempt. This environment has accelerated interest in artificial intelligence and real‑world evidence as tools to predict and prevent costly changes.

Citeline’s partnership with Risklick brings together two complementary strengths: Citeline’s extensive clinical data repository and AI models that evaluate endpoints, inclusion/exclusion criteria, and operational forecasts, and Risklick’s end‑to‑end digital authoring platform powered by an AI assistant for literature review and knowledge‑base integration. The combined offering embeds evidence‑based recommendations directly into the protocol drafting workflow, allowing sponsors to simulate outcomes, optimize patient eligibility, and generate regulatory‑ready documentation in real time. Early adopters report faster concept‑to‑execution cycles and a measurable reduction in amendment likelihood.

Beyond immediate cost savings, the integrated solution signals a shift toward fully connected digital trial ecosystems. By unifying design, operational planning, and disclosure within a single AI‑driven interface, the partnership paves the way for more agile, adaptive studies that can respond to emerging data without disruptive rework. For the broader life‑sciences industry, this collaboration illustrates how strategic data partnerships can unlock scalable automation, ultimately shortening time‑to‑market for new therapies and enhancing patient access. As AI maturity grows, such platforms may become the standard backbone of clinical development.